JP5140224B2 - バルプロ酸のリン脂質誘導体およびそれらの混合物 - Google Patents

バルプロ酸のリン脂質誘導体およびそれらの混合物 Download PDF

Info

Publication number
JP5140224B2
JP5140224B2 JP2002513407A JP2002513407A JP5140224B2 JP 5140224 B2 JP5140224 B2 JP 5140224B2 JP 2002513407 A JP2002513407 A JP 2002513407A JP 2002513407 A JP2002513407 A JP 2002513407A JP 5140224 B2 JP5140224 B2 JP 5140224B2
Authority
JP
Japan
Prior art keywords
vpa
glycero
phosphocholine
valproyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002513407A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004509854A5 (enExample
JP2004509854A (ja
Inventor
コザック、アレクサンダー
Original Assignee
ディ − ファーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディ − ファーム リミテッド filed Critical ディ − ファーム リミテッド
Publication of JP2004509854A publication Critical patent/JP2004509854A/ja
Publication of JP2004509854A5 publication Critical patent/JP2004509854A5/ja
Application granted granted Critical
Publication of JP5140224B2 publication Critical patent/JP5140224B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002513407A 2000-07-12 2001-07-10 バルプロ酸のリン脂質誘導体およびそれらの混合物 Expired - Fee Related JP5140224B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/614,271 2000-07-12
US09/614,271 US6313106B1 (en) 1995-06-07 2000-07-12 Phospholipid derivatives of valproic acid and mixtures thereof
PCT/IL2001/000629 WO2002007669A2 (en) 2000-07-12 2001-07-10 Phospholipid derivatives of valproic acid and mixtures thereof

Publications (3)

Publication Number Publication Date
JP2004509854A JP2004509854A (ja) 2004-04-02
JP2004509854A5 JP2004509854A5 (enExample) 2008-07-17
JP5140224B2 true JP5140224B2 (ja) 2013-02-06

Family

ID=24460534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002513407A Expired - Fee Related JP5140224B2 (ja) 2000-07-12 2001-07-10 バルプロ酸のリン脂質誘導体およびそれらの混合物

Country Status (20)

Country Link
US (2) US6313106B1 (enExample)
EP (1) EP1315506B1 (enExample)
JP (1) JP5140224B2 (enExample)
KR (1) KR100801213B1 (enExample)
CN (1) CN100536851C (enExample)
AT (1) ATE461697T1 (enExample)
AU (2) AU2001270962B8 (enExample)
BR (1) BR0112337A (enExample)
CA (1) CA2415354C (enExample)
CY (1) CY1110113T1 (enExample)
CZ (1) CZ305745B6 (enExample)
DE (1) DE60141636D1 (enExample)
DK (1) DK1315506T3 (enExample)
ES (1) ES2343403T3 (enExample)
HU (1) HU229320B1 (enExample)
IL (1) IL153147A0 (enExample)
MX (1) MXPA03000326A (enExample)
NZ (1) NZ522788A (enExample)
PT (1) PT1315506E (enExample)
WO (1) WO2002007669A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
US7582678B2 (en) 1997-07-09 2009-09-01 D-Pharm Limited Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
US6518311B2 (en) * 1997-07-09 2003-02-11 D-Pharm Ltd. Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
AU2003217791A1 (en) 2002-02-28 2003-09-16 A And D Bioscience, Inc. Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof
WO2003079980A2 (en) * 2002-03-19 2003-10-02 A & D Bioscience, Inc. Caboxylic acid glycuronides, glycosamides and glycosides of quinolones, penicillins, analogs, and uses thereof
WO2003086475A1 (en) * 2002-04-12 2003-10-23 A & D Bioscience, Inc. Conjugates comprising cancer cell specific ligands, a sugar and diagnostic agents, and uses thereof
WO2003094842A2 (en) * 2002-05-07 2003-11-20 A & D Bioscience, Inc. Conjugates comprising central nervous system active drug
US20050215487A1 (en) * 2002-06-27 2005-09-29 Holick Michael F Conjugates comprising an nsaid and a sugar and uses thereof
US20050170063A1 (en) * 2004-01-29 2005-08-04 Lalit Chordia Production of powder and viscous material
GB2460976B (en) * 2005-03-24 2010-02-17 John Marcell Davis Methods of determining compounds useful in the treatment of bipolar disorder and methods of treating such disorders
EP1928807A4 (en) * 2005-09-02 2011-05-04 Picobella Llc ONCOGENIC REGULATORS RNA FOR DIAGNOSIS AND THERAPY
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
KR200451744Y1 (ko) * 2008-10-10 2011-01-10 이종희 휴대용 운동기구
AU2013257710B2 (en) * 2012-05-08 2016-10-20 Cellixbio Private Limited Compositions and methods for the treatment of neurological disorders
CN104230981B (zh) * 2013-06-20 2016-05-18 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的制备方法
PT3429580T (pt) * 2016-03-16 2025-08-12 Buzzelet Development And Technologies Ltd Composição de canabinoides enriquecida em terpenos
CN108659037B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的多晶型物及制备方法
CN108659038B (zh) * 2017-03-31 2022-01-11 江苏恩华药业股份有限公司 1-硬脂酰-2-丙戊酰-sn-甘油-3-磷脂酰胆碱的多晶型物及制备方法
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
CN110407867A (zh) * 2018-04-28 2019-11-05 江苏恩华药业股份有限公司 丙戊酸磷脂衍生物的新晶型及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654370A (en) * 1979-03-12 1987-03-31 Abbott Laboratories Glyceryl valproates
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4558070A (en) 1983-10-26 1985-12-10 Abbott Laboratories Acid salts of valproic acid
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
IT1201149B (it) 1987-01-14 1989-01-27 Indena Spa Complessi di bioflavonoidi con fosfolipidi,loro preparazione,uso e composizioni farmaceutici e cosmetiche
JP3019994B2 (ja) 1987-11-30 2000-03-15 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 新規なオリゴデオキシヌクレオチド、それを使用した標的遺伝子の発現をブロックする方法、及び新規なオリゴデオキシヌクレオチド並びにそれを使用した標的遺伝子の発現を阻止する方法
DE3801587A1 (de) 1988-01-21 1989-08-03 Hoechst Ag Neue aminosaeureglyceride, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
WO1990010448A2 (en) 1989-03-07 1990-09-20 Genentech, Inc. Covalent conjugates of lipid and oligonucleotide
JPH03133987A (ja) 1989-10-18 1991-06-07 Kowa Yakuhin Kogyo Kk ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
AU7872491A (en) 1990-05-07 1991-11-27 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
CH679856A5 (enExample) 1990-07-04 1992-04-30 Lonza Ag
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
CA2112803A1 (en) 1991-07-12 1993-01-21 Karl Y. Hostetler Antiviral liponucleosides: treatment of hepatitis b
US6015834A (en) 1992-10-20 2000-01-18 Toronto Neuroprotection Group In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer
IL105244A (en) * 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US6313106B1 (en) * 1995-06-07 2001-11-06 D-Pharm Ltd. Phospholipid derivatives of valproic acid and mixtures thereof
IL121268A0 (en) * 1997-07-09 1998-01-04 Dpharm Ltd Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders
KR100301803B1 (ko) 1998-06-05 2001-09-22 김영환 박막트랜지스터 및 그의 제조방법

Also Published As

Publication number Publication date
WO2002007669A2 (en) 2002-01-31
IL153147A0 (en) 2003-06-24
EP1315506A2 (en) 2003-06-04
ATE461697T1 (de) 2010-04-15
WO2002007669A3 (en) 2003-01-09
CN100536851C (zh) 2009-09-09
AU7096201A (en) 2002-02-05
KR100801213B1 (ko) 2008-02-05
US20040033987A1 (en) 2004-02-19
CY1110113T1 (el) 2015-01-14
BR0112337A (pt) 2004-06-08
CA2415354C (en) 2009-09-29
EP1315506A4 (en) 2005-03-30
KR20030034099A (ko) 2003-05-01
AU2001270962B2 (en) 2006-03-16
HUP0302635A3 (en) 2007-06-28
DE60141636D1 (de) 2010-05-06
HU229320B1 (en) 2013-10-28
CN1774252A (zh) 2006-05-17
CZ305745B6 (cs) 2016-03-02
HUP0302635A2 (hu) 2003-11-28
CZ200386A3 (cs) 2003-06-18
JP2004509854A (ja) 2004-04-02
AU2001270962B8 (en) 2006-08-10
CA2415354A1 (en) 2002-01-31
DK1315506T3 (da) 2010-05-31
EP1315506B1 (en) 2010-03-24
US6313106B1 (en) 2001-11-06
NZ522788A (en) 2005-04-29
PT1315506E (pt) 2010-05-17
ES2343403T3 (es) 2010-07-30
MXPA03000326A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
KR100801213B1 (ko) 발프로산의 인지질 유도체 및 그 혼합물
AU2001270962A1 (en) Phospholipid derivatives of valproic acid and mixtures thereof
EP2061749B1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
JP2001509500A (ja) 分岐鎖脂肪酸、それらの誘導体、および中枢神経系障害の処置における使用
JP3801225B2 (ja) アミノアルコール類の塩およびこれを含有する医薬処方物
US5202313A (en) Bilobalide derivatives, their applications and formulations containing them
JP2007510737A (ja) 癌処置のためのセラミド異化阻害剤としてのｐｐｍｐ
US6518311B2 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
JP2022538505A (ja) ミクロ分子ｐｉ４ｋｉｉｉａ阻害剤組成物、その調製方法およびその使用
JP2019529517A (ja) ニトロソ化およびアルキル化反応を媒介するニトロアルケンの新規可逆的窒素酸化物誘導体
CA2091550A1 (en) New derivatives of physostigmine, their use and pharmaceutical formulations containing them
AU2014201024A1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
JP2514995B2 (ja) 経皮、経粘膜による物質の吸収を促進する組成物
JP2022548458A (ja) イブプロフェンエステル系プロドラッグ、医薬組成物、調製方法および使用
IL153147A (en) Pharmaceutical compositions comprising phospholipid conjugates of valproic acid or derivatives thereof
KR100263085B1 (ko) 신규의 알카로이드 유도체, 이의 용도 및 이를 함유한 제약적 조성물
EP1167353A1 (en) Morphan derivatives or salts thereof and medicinal compositions containing the same
EP3110412B1 (en) 4-benzylsulfonyl-2-butenenitrile
AU2006347925B2 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120815

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121030

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121119

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151122

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees